- Home
- ZION vs JAZZ Comparison
ZION vs JAZZ Comparison
Compare ZION & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZION
- JAZZ
- Stock Information
- Founded
- ZION 1873
- JAZZ 2003
- Country
- ZION United States
- JAZZ Ireland
- Employees
- ZION N/A
- JAZZ N/A
- Industry
- ZION Major Banks
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- ZION Finance
- JAZZ Health Care
- Exchange
- ZION Nasdaq
- JAZZ Nasdaq
- Market Cap
- ZION 7.4B
- JAZZ 8.4B
- IPO Year
- ZION N/A
- JAZZ 2007
- Fundamental
- Price
- ZION $49.47
- JAZZ $122.92
- Analyst Decision
- ZION Hold
- JAZZ Strong Buy
- Analyst Count
- ZION 22
- JAZZ 13
- Target Price
- ZION $59.24
- JAZZ $187.15
- AVG Volume (30 Days)
- ZION 2.3M
- JAZZ 1.3M
- Earning Date
- ZION 04-21-2025
- JAZZ 04-30-2025
- Dividend Yield
- ZION 3.48%
- JAZZ N/A
- EPS Growth
- ZION 13.92
- JAZZ 41.75
- EPS
- ZION 4.95
- JAZZ 8.65
- Revenue
- ZION $3,058,000,000.00
- JAZZ $4,068,950,000.00
- Revenue This Year
- ZION $9.91
- JAZZ $7.30
- Revenue Next Year
- ZION $5.06
- JAZZ $4.01
- P/E Ratio
- ZION $9.99
- JAZZ $14.21
- Revenue Growth
- ZION 2.51
- JAZZ 6.12
- 52 Week Low
- ZION $39.05
- JAZZ $99.06
- 52 Week High
- ZION $63.22
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- ZION 42.02
- JAZZ 32.69
- Support Level
- ZION $48.53
- JAZZ $137.74
- Resistance Level
- ZION $51.99
- JAZZ $142.64
- Average True Range (ATR)
- ZION 1.38
- JAZZ 3.87
- MACD
- ZION 0.39
- JAZZ -2.12
- Stochastic Oscillator
- ZION 56.55
- JAZZ 0.45
About ZION Zions Bancorporation N.A.
Zions Bancorporation is a regional us bank with core operations that span 11 states. The bank is headquartered in Salt Lake City and does business primarily in the Western and Southwestern United States. Zions primarily focuses on providing banking services to small and midsize businesses, with the bulk of its loans focused on commercial and commercial real estate lending.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.